CORT vs TMO · P/E 199, rev $675.0M vs P/E 24, rev $44.56B
Corcept Therapeutics Incorporated (CORT) versus Thermo Fisher Scientific Inc (TMO) — a side-by-side from cached financials, not a winner call.
Corcept Therapeutics Incorporated (CORT) is a biotechnology company listed on US.
Thermo Fisher Scientific Inc (TMO) is a diagnostics & research company listed on US.
Latest reported CORT revenue for 2024-12-31 was $675.0M. Net income was $141.2M. Revenue was up 39.9% from 2023-12-31 to 2024-12-31. CORT currently screens at market cap $7.46B and trailing P/E 198.5.
Latest reported TMO revenue for 2025-12-31 was $44.56B. Net income was $6.70B. Revenue was up 3.9% from 2024-12-31 to 2025-12-31. TMO currently screens at market cap $153.06B and trailing P/E 23.8.
CORT currently screens at market cap $7.46B and trailing P/E 198.5. TMO currently screens at market cap $153.06B and trailing P/E 23.8.
Not investment advice. Open the CORT and TMO stock pages for the full models.
Not investment advice.